Printer Friendly

BREAST CANCER PREVENTION TRIAL PRESS CONFERENCE TO BE HELD APRIL 29

BREAST CANCER PREVENTION TRIAL PRESS CONFERENCE TO BE HELD APRIL 29
 What: Press Conference -- Breast Cancer Prevention Trial
 (BCPT)
 When: Wednesday, April 29, at 10 a.m.
 Where: College of Physicians of Philadelphia, 19 S. 22nd St.
 (between Market and Chestnut streets), Thomson Hall
 1st floor, Philadelphia.
 Details:
 Four Philadelphia medical institutions -- Albert Einstein Cancer Center, Bryn Mawr Hospital Cancer Center, Fox Chase Cancer Center, and University of Pennsylvania Cancer Center -- have been selected as primary sites for the Breast Cancer Prevention Trial, a nationwide clinical trial to determine the effectiveness of tamoxifen in preventing breast cancer in women at risk. Conducted by the National Surgical Adjuvant Breast and Bowel Project and sponsored by the National Cancer Institute, this national investigation hopes to attract more than 16,000 women throughout the country.
 Principal investigators from each of these four participating institutions will discuss and answer questions about the purpose of the trial and details of the protocol. In addition, two women, who hope to become participants in the trial, will speak about the risk factors that motivate them.
 CONTACT: Annemarie Armstrong of Albert Einstein Cancer Center, 215-456-6734, or Ellen Mattes of Bryn Mawr Hospital Cancer Center, 215-526-3033, or Eric Rosenthal of Fox Chase Cancer Center, 215-728-2700, or Rebecca Harmon of the University of Pennsylvania Cancer Center, 215-349-5660.
 /delval/
 -0- 4/20/92


CO: Albert Einstein Cancer Center; Bryn Mawr Hospital Cancer Center;
 Fox Chase Cancer Center; University of Pennsylvania Cancer Center ST: Pennsylvania IN: HEA SU:


MP-KA -- PH034 -- 0150 04/20/92 14:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1992
Words:255
Previous Article:PPG INDUSTRIES TO HOLD NEWS CONFERENCE
Next Article:MARTIN MARIETTA ACQUIRES 50 PERCENT INTEREST IN KASER CORPORATION


Related Articles
FDA Advisory Committee Urged To Reject Zeneca's Application of Tamoxifen For Preventing Breast Cancer in Healthy Women as the Drug is Ineffective and...
Keystone Breast Cancer Conference Lilly Luncheon And Pink Ribbon Awards Ceremony.
First Lady, Kathy Schweiker Partner For Statewide Breast Cancer Conference.
Three Boston Hospitals to Participate in National Breast Cancer Trial.
Minnesota Cancer Researchers Announce Participation in Major Breast Cancer Prevention Trial.
/C O R R E C T I O N -- Young Survival Coalition/.
Allegheny General Hospital and National Surgical Adjuvant Breast and Bowel Project Executive, Joan Beyer Goldberg, to Receive the Pennsylvania Breast...
Therion Biologics to Present at Mass Opportunities Biotechnology Investment Conference; -- Company to Provide Overview of Late-stage Clinical...
BioVex's OncoVEX(GM-CSF) Clinical Trial Data to Be Featured by American Association for Cancer Research at 96th Annual Meeting; - OncoVEX Results...
BioVex's OncoVEX(GM-CSF) Clinical Trial Data to Be Featured by American Association for Cancer Research at 96th Annual Meeting.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters